Skip to content Skip to left sidebar Skip to footer


PhilaVax Temperature Reporting Requirement Update

PhilaVax Temperature Reporting Requirement Update

Important: VFC & VFAAR orders submitted to PhilaVax without temperature data will be rejected. *

We will no longer contact VFC & VFAAR sites to request missing temperature data after the order date. VFC & VFAAR orders will be rejected, and the provider will need to resubmit their order. Remember, a new reconciliation must be completed after two business days to process the order. 

Uploading temperature data to PhilaVax and emailing the data to have been requirements for several years. The data you submit to the TempCheck team is analyzed for excursions and potential unit malfunctions, helping us maintain our quality control standards. The data submitted to PhilaVax facilitates timely ordering for our 200+ providers throughout the city.  

These guide
s can assist you in submitting your DDL temperature files:

Key Takeaways:

  • Temperature data must be submitted to PhilaVax and emailed to every 28 days and when an order is placed.
  • Submit temperature data up to and including the day of vaccine order.
  • For example, if you submit temperature data on Monday and place your order on Tuesday, you must submit temperatures again on Tuesday, or your order will be rejected.
  • After placing an order, it’s important to check its status within two business days. If the order is rejected, carefully review the VFC comments for instructions on resubmitting it. Remember, a new reconciliation must be completed after two business days to process the order.

For questions and assistance with ordering, reach out to

*If you are unable to upload to PhilaVax for any reason or feel your site should be exempt from this requirement, please contact

New Vaccine Product Available Through VFC: Penbraya (MenABCWY)

New Vaccine Product Available Through VFC: Penbraya (MenABCWY)

On October 20, 2023, the FDA licensed Pfizer’s pentavalent vaccine Penbraya to prevent meningococcal serogroups A, B, C, W, and Y.

As a reminder, MenB vaccines are not interchangeable. The same vaccine (either Bexsero by GSK or Trumenba by Pfizer) must be used for all doses in the MenB series, including booster doses. The pentavalent MenABCWY product Penbraya (Pfizer) contains MenB-Fhbp (Trumenba) as its MenB component; therefore, Penbraya should only be used in series with Trumenba.

To add this formulation to the list of vaccines that your site orders, use the button below to complete the change request form.

Our team will review your request and reply with next steps. We recommend that sites that are affiliated or part of a system use the same vaccine presentations across sites to ensure continuity of care and help prevent administration errors.

To purchase this vaccine in the private market, please contact your local Pfizer sales rep at

Penbraya 1 Dose Kit and Penbraya 5 Dose Kit are now available through the Vaccines for Children (VFC) program. 

  • The Advisory Committee on Immunization Practices (ACIP) recommends MenABCWY for ages 10 through 25. Penbraya may be used when both MenACWY and MenB are indicated at the same visit. More specifically, MenABCWY is recommended for the following groups based on shared clinical decision-making:
  • Healthy individuals aged 16 to 23 years due for their MenACWY booster and MenB vaccination at the same visit. 
  • Children 10 years and older with complement deficiency, functional or anatomic asplenia (including sickle cell disease), or receiving complement inhibitors. 
  • CVX code: 316 
  • CPT code: 90623 
  • NDC number: 00069-0600-01 (1 Dose Kit) and 00069-0600-05 (5 Dose Kit) 


If you have any questions, please email

2024 Influenza Ordering Survey

Congratulations to last week’s survey winner: Puentes De Salud! But wait, there’s another chance to win and help us better prepare for the next flu season! We will hold a second drawing to win a free buzzy

To enter our second drawing, use the button below to complete a short survey (less than 3 minutes) by Friday, May 17, 2024.  

If you previously filled out the survey, you’ve already entered. Your responses are key to our 2024-2025 flu season planning!

2024 Influenza Ordering Survey

2024 Influenza Ordering Survey

While flu remains prevalent across the country, the 2023-2024 flu season has seen a drop in coverage, and Philadelphia is no exception.   

Fill out this short survey (less than 3 minutes) to help us better prepare for next flu season. Every site that completes the form by Friday, April 26, 2024, will be entered for a chance to win a free buzzy. Your responses are key in our planning for the 2024-2025 flu season! 

Pediatric Immunization Techniques Training 

Pediatric Immunization Techniques Training 

Join us for a pediatric immunization techniques training for Vaccines for Children (VFC) providers!  

The Immunization Program is hosting a free pediatric immunization techniques training for VFC providers. Class participants are limited and will be taken on a first-come, first-served basis. A maximum of 21 participants will be accepted. Participants can only attend one training per year.

This half-day, interactive training is tailored to VFC sites only and will focus on the basics of:

  • Vaccine preventable diseases 
  • Vaccine types
  • Immunization administration techniques 
  • Pediatric immunization schedules

Training Details: 

Hosts: Division of Disease Control, Immunization Program 

Date: Thursday, May 16, 2024

Time: 8:30 a.m. – 12:30 p.m.

Location: Jefferson Center 1101, Market St., 13th Floor, Training Room Phila., PA 19107


  • Beth Smith, BSN, RN – Provider Quality Assurance Nurse
  • Dom Shannon, BSN, RN – Provider Quality Assurance Nurse
  • Nichole Holmes, MPH – Training Coordinator 

We encourage attendance by RNs, LPNs, and MAs who administer vaccines or will administer vaccines in the future. This course is beneficial to new and seasoned practitioners who need a refresher or would like an update on best practices for administering vaccines.

Important note: This training does not offer continuing education credits/units. Upon completion, a certificate will be distributed. We hope to see you there!

If you have any questions, reach out to

RSV Season Ends March 31

RSV Season Ends March 31

As the respiratory syncytial virus (RSV) season draws to a close on March 31, we want to remind all healthcare providers of important considerations regarding administering nirsevimab (Beyfortus) and RSV immunization. 

  • End of RSV season: The RSV season officially concludes on March 31. Therefore, it is essential to administer all remaining doses of nirsevimab to eligible children before April 1. 
  • Do not discard unused immunizations: If you possess surplus doses of nirsevimab at the end of this RSV season, do not discard them. The expiration date for Beyfortus has been extended to two years. These doses can be safely stored and utilized when the RSV season resumes on October 1.   

We recognize the challenges encountered during this RSV season and extend our gratitude to all healthcare providers for their patience, flexibility, and perseverance. According to the CDC’s latest data, 43% of newborns received RSV coverage this year despite the limited availability of Beyfortus.

If you have any questions or require further guidance, please contact Victor Obeck, VFC coordinator, at

Catch Up Pediatric Patients: MMR Vaccine

Catch Up Pediatric Patients: MMR Vaccine

There is a measles cluster in Philadelphia that started with an infant and spread to unvaccinated individuals. It has resulted in now 7 confirmed cases of measles among Philadelphia residents and an index case in Delaware county.

To prevent further spread, review your pediatric patients’ records for MMR vaccine and recall any patients who are not up to date. Consider nurse-only visits to get patients in faster. 

Measles is highly infectious and can be especially dangerous to children under 5, pregnant people, and immunocompromised individuals. CDC recommends children get their first MMR dose at 12-15 months and the second dose at 4-6 years. 

You can order a free measles flyer below.

Vaccine Product Available Through VFC: Abrysvo

Vaccine Product Available Through VFC: Abrysvo

Abrysvo is a maternal RSV vaccine available through the Vaccines for Children (VFC) program. 

RSV is surging and the pediatric infant immunization Beyfortus supply is severely limited. Abrysvo will play an important role in protecting infants against severe RSV disease this season. Most infants born to mothers who have received Abrysvo will not need to receive Beyfortus. 

Please note that the availability of Abrysvo for VFC providers is limited. Only sites that care for pregnant people under 19 can order, and orders will be limited to 5 doses per site at a time.


Abrysvo is a Pfizer product now available through the Vaccines Children (VFC) program.

  • CVX code: 305
  • CPT code: 90678
  • NDC number: 00069-0344-01

V-safe, one of several systems CDC uses to closely monitor the safety of vaccines, will be used as a health check for pregnant people who receive a maternal RSV vaccine.

For more information, review the package insert.

Additional resources:

FDA page

If you have any questions, please email

Administration Errors: RSV for Infants

Administration Errors: RSV for Infants

On November 30, CDC alerted immunization programs that they have received reports of infants being mistakenly administered RSV vaccines intended for adults. Infants should only receive the RSV preventive antibody, nirsevimab (Beyfortus, Sanofi).

RSV vaccines (Arexvy by GSK and Abrysvo by Pfizer) are recommended only for adults and have not been evaluated for safety or effectiveness in infants or children. Practices that carry both adult RSV vaccine and pediatric RSV preventive antibody products should review their immunization administration safety procedures to ensure only the correct product is administered to recipients. This is an opportunity to re-educate and re-train staff on RSV immunization formulations and practices.

In the event that a vaccine administration involving RSV vaccine occurs, CDC encourages vaccinators to promptly report errors to the Vaccine Adverse Event Reporting System (VAERS). Also, inform parents of error so that these infants can receive the correct product and be monitored for adverse reactions. 

CDC Clinical Guidance (updated December 7, 2023)

Because there are no data on the efficacy/effectiveness of RSV vaccines in preventing RSV disease in this age group, the infant should receive nirsevimab if otherwise eligible based on maternal RSV vaccination status. There is no specific recommendation for a minimum interval between administration of incorrect RSV vaccine and nirsevimab. Some experts suggest:

• That it could be reasonable to consider waiting 48 to 72 hours before proceeding with nirsevimab administration. This time frame is when we would expect side effects to the RSV vaccine, such as fussiness, would be most likely.

• Consideration should be given to administering nirsevimab in the limb opposite to where the RSV vaccine was administered to avoid potential interaction or binding of RSV antibody and vaccine, thereby reducing the effectiveness of nirsevimab.

If further clinical guidance is needed, connect with our medical experts at or CDC experts at

Quality Improvement Opportunity for VFC Providers

Quality Improvement Opportunity for VFC Providers

The Immunization Quality Improvement for Providers (IQIP) Program is a CDC initiative to help providers implement strategies that support their immunization activities.

VFC-enrolled practices are chosen by the CDC for IQIP enrollment each year. However, starting this project year (July 1, 2023 to June 30, 2024), VFC-enrolled practices may self-enroll in IQIP.

Practices that do not have pediatric patients capitated to them (e.g., shelter sites, sexual health clinics, and birthing hospitals) are not eligible to participate.

Why self-enroll in IQIP?

IQIP helps practices meet their goals of efficient and effective vaccination processes to ensure timely and complete vaccine coverage for all children.

How can IQIP participation serve pediatric departments and physicians?

  • IQIP efforts can be converted to group quality improvement (QI) projects, which can be eligible to fulfill the American Board of Pediatrics maintenance of certification (MOC) Part 4 requirements
  • IQIP can help residency programs develop QI projects and educational opportunities
  • Through IQIP, departments can meet national immunization quality metrics

What does IQIP offer?

Provider Quality Assurance (PQA) nurses through the Philadelphia Department of Health (PDPH) Immunization Program, in partnership with the CDC, offer guidance, practical recommendations, and technical support to practices aiming to increase their vaccination coverage rates.

The focus of IQIP is based on four CDC core strategies:

1. Facilitate patient return for vaccination
2. Leverage Immunization Information Systems (IIS) functionality to improve immunization practice.
3. Give a strong vaccine recommendation
4. Strengthen vaccination communications

Get in touch!

To enroll your practice in IQIP, contact your VFC Program PQA nurse Beth Smith at, Dom Shannon at, or Jennifer Malins at

For more information on how IQIP can serve pediatric departments and physicians, please contact our newly onboarded Immunization Program Medical Specialist, Dr. Mayssa Abuali, at

Learn more about IQIP!